Skip to main content

Table 4 Clinical outcomes by treatment group

From: The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients

 

PMX-HP group

Non PMX-HP group

P valuea

Overall

n = 29

n = 30

 

 Mortality on day 3, n (%)

3 (10.3)

10 (33.3)

0.058

 Mortality on day 7, n (%)

6 (20.7)

12 (40.0)

0.11

 Mortality on day 28, n (%)

17 (58.6)

15 (50.0)

0.51

 MAKE 28b (%)

22 (75.9)

22 (73.3)

1.00

Alive on day 28

n=13c

n = 15

 

 ICU-free days (Q1, Q3)

0 (0, 10)

0 (0, 8)

0.99

 Ventilator-free days (Q1, Q3)

0 (0, 8)

0 (0, 0)

0.28

 RRT, n (%)

7 (53.8)

6d (50.0)

0.85

 Serum creatinine (mg/dl) (Q1, Q3)

1.4 (1.1, 2.2)

2.1 (1.3, 2.5)

0.59

 Vasopressor free days (Q1, Q3)

0 (0, 25)

11.5 (0, 25)

0.47

AKI at baseline

n = 25

n = 25

 

 Renal recoverye, n (%)

5 (20.0)

3 (12.0)

0.70

  1. Data represent median (25th percentile, 75th percentile) unless otherwise noted
  2. Data measured on day 28 unless otherwise noted
  3. PMX-HP polymyxin B hemoperfusion, ICU intensive care unit, Q1 25th percentile, Q3 75th percentile, RRT renal replacement therapy, AKI acute kidney injury
  4. aFisher’s exact test for categorical variables; Kruskal–Wallis test for continuous variables
  5. bMajor adverse kidney events on day 28, comprised of death, or dialysis dependence, or persistent AKI on day 28
  6. cIn the PMX-HP group one patient died by the end of day 28, but his values were measured and used in the analysis
  7. dIn the non-PMX-HP group, RRT data were available in 12 patients
  8. eRenal recovery mean alive, dialysis independence and no AKI on day 28 after enrollment
Back to article page

Critical Care

ISSN: 1364-8535